Author

Marco Torregroza Otero

Observed names: M Otero, M. Torregroza Otero

Observed institutions: University of California, San Francisco, Princess Margaret Cancer Centre, Seoul National University Hospital, IDCQ Hospitales y Sanidad, S.L.U., Pontifícia Universidade Católica do Rio Grande do Sul, Universidad Europea de Madrid

OpenAlex ID: A5049777635

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

2020 · Javier Cortes, David W Cescon, et al. · The Lancet · 1,797

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

2022 · Javier Cortes, Hope S. Rugo, et al. · New England Journal of Medicine · 1,192

KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

2020 · Javier Cortes, David W. Cescon, et al. · Journal of Clinical Oncology · 186

LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

2021 · J. Cortés, D.W. Cescon, et al. · Annals of Oncology · 53

Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

2021 · Hope S. Rugo, Peter Schmid, et al. · Cancer Research · 25

Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355

2023 · David W Cescon, Peter Schmid, et al. · JNCI Journal of the National Cancer Institute · 23

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

2022 · Javier Cortes, David W. Cescon, et al. · Cancer Research · 11

[Anesthesia for the patient with cancer].

2001 · P Monedero, R Calderón, et al. · PubMed · 1

Outcomes in KEYNOTE-355 after chemotherapy discontinuation before pembrolizumab discontinuation and with immune-mediated adverse events

2026 · Hope S. Rugo, David W. Cescon, et al. · npj Breast Cancer

Works count: 9

Citation count: 3,282

H-index: 7

I10-index: 7